Tag : MAJOR ADVERSE CARDIOVASCULAR EVENTS

Whether the timing of administering antihypertensive medication affects major adverse cardiovascular events (MACEs) is highly uncertain due to conflicting results from randomized trials. While the MAPEC trial in 2010 and Hygia trial in 2019 showed significant reductions in MACE (61% and 45% respectively) when blood pressure (BP) medications were taken at bedtime instead of conventional morning use, the TIME trial in 2022 showed no additional benefit in doing so. The BedMed and BedMed-Frail trials were thus conducted to investigate these contradictory findings in a hypertensive primary care population, as well as in older, hypertensive patients living in continuing care wards. The outcomes of the trials were presented at the ESC Congress 2024 by Professor Scott Garrison from the University of Alberta in Canada.